DNDorothy Chiwoniso Nyemba

Dorothy Chiwoniso Nyemba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dorothy Chiwoniso Nyemba has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Landon Myer

    Division of Epidemiology and Biostatistics, School of Public Health, University of Cape Town, Cape Town, South Africa

    9 shared publications
  • Amy L. Slogrove

    Department of Paediatrics & Child Health, Faculty of Medicine & Health Sciences, Stellenbosch University, Worcester, South Africa

    3 shared publications
  • Andrew Boulle

    Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa

    3 shared publications
  • Emma Kalk

    Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa

    3 shared publications
  • Hlengiwe P. Madlala

    Division of Epidemiology & Biostatistics, Faculty of Health Sciences, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa

    3 shared publications
  • Leigh F. Johnson

    University of Cape Town

    3 shared publications

Latest Publications

  • Screening and prevalence of Gonorrhea and Chlamydia in inner-city Johannesburg: Findings from recruitment for a clinical trial on a novel antibiotic

    by Dorothy C. Nyemba, Danielle Travill, Lucky Molefe, Audrey Dhlamini, Lerato Lunika, Sinead Delany-Moretlwe

    Sexually transmitted infections are endemic in South Africa, partly because of the limitations of syndromic management as the standard approach. In recruitment initiative for a novel gonorrhea antibiotic trial, 8189 adults aged ≥18 years were reached and 3381 tested for Chlamydia and Gonorrhea, revealing high prevalence, especially among young people.

  • Open Access

    Impact of antenatal screening for Chlamydia and Gonorrhea on pregnancy outcomes in South African women

    by Dorothy Chiwoniso Nyemba, Alex de Voux, Rufaro Mvududu, Remco P. H. Peters, Sinead Delany-Moretlwe, Leigh F. Johnson, Thomas J. Coates, Landon Myer, Dvora Leah Joseph Davey

    Background: We evaluated the impact of diagnosing and treating curable STIs during pregnancy on adverse pregnancy outcomes in Cape Town, South Africa. Methods: Eligible women ≥ 15 years, without HIV, attending first antenatal care (ANC) visit before 28 weeks gestation, received diagnostic testing at enrolment and either same-day or follow-up treatment for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) using either on-site GeneXpert or laboratory-based testing with TaqMan qPCR assays. We assessed prevalence of CT/NG, time to treatment and the frequency of poor pregnancy outcomes, individually and combined including pregnancy loss (miscarriage [< 20weeks] or stillbirth [≥ 20weeks]) and perinatal outcomes (low birthweight [< 2500 g], preterm birth [< 37weeks], small for gestational age [< 10th percentile] and neonatal death [< 7days]) among women with or without CT/NG at study enrolment. Logistic regression models evaluated the impact of time to CT/NG treatment on the frequency of individual and combined poor pregnancy outcomes, adjusting for maternal characteristics. Results: Among 1237 pregnant women, the prevalence of CT/NG at first ANC visit was 28% (24% CT, 8% NG). Of those diagnosed with CT/NG ( n = 345), 54% received immediate treatment(< 7 days), while 34% experienced delayed treatment (median time to treatment 28 days (interquartile range: 15–57)) and 12% were untreated during pregnancy. Among women with CT/NG, the frequency of miscarriage (12%) and stillbirth (9%) were highest among women with untreated CT/NG, lower among delayed treatment (4% and 3%), and lowest among immediate treatment (1% and 2%), respectively. Among women with CT/NG at enrolment, poor pregnancy outcome was 28%, 23%, and 29% for immediate, delayed, and no treatment, respectively; 22% among women with no CT/NG at enrolment (overall χ² test, p = 0.05). Untreated CT/NG were associated with increased odds of pregnancy loss (adjusted odds ratio (aOR); 3.27, 95% CI: 1.09–9.80) compared to CT/NG with immediate treatment and compared to no CT/NG at study enrolment (aOR; 5.05, 95% CI: 2.23–11.43). Multivariable analysis showed no significant difference in poor pregnancy outcome by time to CT/NG treatment. Conclusion: Untreated CT/NG during pregnancy increased the odds of experiencing a miscarriage or stillbirth. These findings suggest potential benefits of STI screening using diagnostic tests leading to the timely treatment of curable STIs in pregnancy, and randomized trials are urgently needed to clarify these effects. Clinical trial number: Not applicable.

  • Open Access

    The impact of HIV on cervical cancer elimination in KwaZulu-Natal: a comparative modeling analysis

    by Christine L Hathaway, Michaela Hall, Daniël de Bondt, Cara J Broshkevitch, Darcy W Rao, Sydney Klein, Dorothy C Nyemba, Danielle Travill, Sinead Delany-Moretlwe, Karen Canfell, et al.

    Background: Achieving cervical cancer (CC) elimination requires addressing disparities in CC burden for women living with HIV (WLHIV) and how disparities evolve in the context of antiretroviral therapy (ART) scale-up. To inform CC elimination for high HIV prevalence regions, we modeled the impact of HIV, HIV interventions, and CC interventions in KwaZulu-Natal, South Africa. Methods: We used 2 independently developed, dynamic compartmental transmission models of HIV and human papillomavirus (DRIVE and Policy1-Cervix-HIV) calibrated to KwaZulu-Natal. We simulated: a counterfactual without HIV but with observed CC screening and vaccination; and scenarios sequentially adding condom use and voluntary medical male circumcision (VMMC); HIV; observed HIV and CC interventions (status quo); achieving United Nations Programme on HIV/AIDS HIV treatment targets; and achieving World Health Organization (WHO) CC elimination targets. The impact of each scenario was measured as the difference in CC incidence from the previous scenario. Results were reported from 2024 to 2124 as a range between the 2 models; CC elimination was WHO-defined as incidence <4/100 000 women-years. Results: For the status quo, CC incidence ranged from 61.30 to 78.96/100 000 women-years in 2024, with the highest incidence among WLHIV (126.8-192.0/100 000). HIV contributed an estimated 29.08-48.87 additional cases per 100 000. Neither model predicted elimination under status quo interventions, but achieving HIV treatment and CC elimination targets could reduce incidence to 1.42-6.25/100 000 women-years in 2124. Conclusions: HIV is associated with a population-level increase in CC incidence. However, scaling up ART coverage and CC interventions is expected to significantly reduce the burden of CC overall and among WLHIV. These conclusions are consistent between both models and strengthened by the comparative modeling approach.


  • Open Access

    The effect of STI screening during pregnancy on vertical transmission of HIV and adverse pregnancy outcomes in South Africa: a modelling study

    by Dorothy C. Nyemba, Dvora L. Joseph‐Davey, Sinead Delany‐Moretlwe, Landon Myer, Leigh F. Johnson

    Introduction: Sexually transmitted infections (STIs) in pregnancy are associated with an increased risk of vertical HIV transmission and adverse pregnancy and birth outcomes. In South Africa, syndromic management is the standard of care for STI management. We assessed the potential impact of point‐of‐care (POC) screening for curable STIs ( Chlamydia trachomatis [CT], Trichomonas vaginalis [TV] and Neisseria gonorrhoeae [NG]) during pregnancy on vertical HIV transmission and adverse pregnancy and birth outcomes. Method: We developed a static mathematical model to estimate the impact of syndromic management compared to POC screening of STIs in pregnant women attending antenatal clinics in South Africa over one calendar year (2022). Our model assumptions regarding the effect of CT, NG and TV on adverse pregnancy/birth outcomes and vertical HIV transmission were informed by two separate meta‐analyses that we conducted. Local studies informed estimates of STI prevalence, POC screening uptake and treatment, and sensitivity of syndromic management. Results: In the absence of POC screening for curable STIs, 25.5% of pregnant women without HIV and 34.6% of pregnant women living with HIV were estimated to have undiagnosed and untreated STIs. In the POC scenario, 92% (95% CI: 85−100%) of STIs were diagnosed and treated during pregnancy, reducing antenatal maternal HIV incidence by 10.0% (95% CI: 1.0−20.1%). Overall, vertical HIV transmission was anticipated to reduce by 8.6% (5.2−13.8%), with reductions of 20.9% (15.2−27.0%) at birth and 2.5% (−0.9% to 9.0%) postnatally, in the POC screening scenario compared to current syndromic management. POC screening of curable STIs is further estimated to reduce the incidence of stillbirth by 10.1% (1.3–18.7%), preterm delivery by 6.3% (3.4–9.7%), infants born small for gestational age by 2.7% (0.7–4.9%) and low birth weight by 9.1% (0.9–18%). Conclusions: POC STI screening and treatment may modestly reduce maternal HIV incidence, vertical HIV transmission, and the risk of adverse pregnancy and birth outcomes, and would substantially reduce the burden of curable STIs in pregnancy. The study provides evidence to move beyond the syndromic management of STIs in South Africa, particularly in antenatal care.


  • Open Access

    Adherence challenges with daily oral pre‐exposure prophylaxis during pregnancy and the postpartum period in South African women: a cohort study

    by Dvora Joseph Davey, Dorothy C. Nyemba, Jose Castillo‐Mancilla, Lubbe Wiesner, Jennifer Norman, Rufaro Mvududu, Nyiko Mashele, Leigh F. Johnson, Linda‐Gail Bekker, Pamina Gorbach, et al.

    Introduction: Daily oral pre‐exposure prophylaxis (PrEP) can reduce HIV acquisition. However, prevention effectiveness requires daily adherence prior to and during periods of sexual activity. Little is known about pharmacologic measures of PrEP adherence during pregnancy and postpartum and the factors related to optimal adherence during periods of sexual activity in this population.Methods: Between August 2019 and October 2021, we enrolled pregnant women without HIV at their first antenatal care visit followed‐up through 12 months postpartum. Eligible women ≥16 years old received HIV prevention counselling and were offered oral PrEP (TDF‐FTC). We quantified tenofovir‐diphosphate (TFV‐DP) in dried blood spots in women who reported taking PrEP in the past 30 days (at quarterly follow‐up visits). We used regression models with generalized estimating equations to evaluate correlates of TFV‐DP (any vs. none, and ≥2 vs. <2 doses/week), adjusting for maternal age and pregnancy status.Results and discussion: In 382 women who started PrEP in pregnancy, returned for follow‐up and reported PrEP use in the past 30 days, the median age was 27 years (interquartile range [IQR] = 23–32), and the median time on PrEP was 168 days (IQR = 84–252 days). Half of the samples had quantifiable TFV‐DP at any time point (52%), declining from 67% of pregnant women 3 months post‐initiation to 31% of postpartum women by 12 months. Overall, 72% had concentrations corresponding to 5/month vs. no sex or <5 times/month = 2.11; 95% CI = 1.58–2.82) adjusting for age and pregnancy versus postpartum status. TFV‐DP concentrations declined over follow‐up time (aOR for 6 vs. 3 months = 0.49; 95% CI = 0.36–0.67).Conclusions: Objectively measured adherence to PrEP was low overall and did not correlate with self‐reported use. There is an urgent need for objective adherence measures to support clinical decision‐making as well as adherence support interventions as part of PrEP services for pregnant and postpartum women at risk of HIV.


  • Open Access

    Impact of aetiological screening of sexually transmitted infections during pregnancy on pregnancy outcomes in South Africa

    by Dorothy C. Nyemba, Remco P. H. Peters, Andrew Medina-Marino, Jeffrey D. Klausner, Phuti Ngwepe, Landon Myer, Leigh F. Johnson, Dvora L. Joseph Davey

    Sexually transmitted infections (STIs) during pregnancy may increase the risk of adverse pregnancy outcomes. STI syndromic management is standard of care in South Africa but has its limitations. We evaluated the impact of diagnosing and treating curable STIs during pregnancy on adverse pregnancy and birth outcomes. We combined data from two prospective studies of pregnant women attending public sector antenatal care (ANC) clinics in Tshwane District and Cape Town, South Africa. Pregnant women were enrolled, tested and treated for STIs. We evaluated the association between any STI at the first ANC visit and a composite adverse pregnancy outcome (miscarriage, stillbirth, preterm birth, early neonatal death, or low birthweight) using modified Poisson regression models, stratifying by HIV infection and adjusting for maternal characteristics. Among 619 women, 61% (n = 380) were from Tshwane District and 39% (n = 239) from Cape Town; 79% (n = 486) were women living with HIV. The prevalence of any STI was 37% (n = 228); C. trachomatis, 26% (n = 158), T. vaginalis, 18% (n = 120) and N. gonorrhoeae, 6% (n = 40). There were 93% (n = 574) singleton live births, 5% (n = 29) miscarriages and 2% (n = 16) stillbirths. Among the live births, there were 1% (n = 3) neonatal deaths, 7% (n = 35) low birthweight in full-term babies and 10% (n = 62) preterm delivery. There were 24% (n = 146) for the composite adverse pregnancy outcome. Overall, any STI diagnosis and treatment at first ANC visit was not associated with adverse outcomes in women living with HIV (adjusted relative risk (aRR); 1.43, 95% CI: 0.95–2.16) or women without HIV (aRR; 2.11, 95% CI: 0.89–5.01). However, C. trachomatis (aRR; 1.57, 95% CI: 1.04–2.39) and N. gonorrhoeae (aRR; 1.69, 95% CI: 1.09–3.08), were each independently associated with the composite adverse outcome in women living with HIV. Treated STIs at the first ANC visit were not associated with adverse pregnancy outcome overall. In women living with HIV, C. trachomatis or N. gonorrhoeae at first ANC were each independently associated with adverse pregnancy outcome. Our results highlights complex interactions between the timing of STI detection and treatment, HIV infection and pregnancy outcomes, which warrants further investigation.


  • Open Access

    Growth patterns of infants with in- utero HIV and ARV exposure in Cape Town, South Africa and Lusaka, Zambia

    by Dorothy C. Nyemba, Emma Kalk, Michael J. Vinikoor, Hlengiwe P. Madlala, Mwangelwa Mubiana-Mbewe, Maureen Mzumara, Carolyn Bolton Moore, Amy L. Slogrove, Andrew Boulle, Mary-Ann Davies, et al.

    Background: Infants born HIV-exposed yet remain uninfected (HEU) are at increased risk of poorer growth and health compared to infants born HIV-unexposed (HU). Whether maternal antiretroviral treatment (ART) in pregnancy ameliorates this risk of poorer growth is not well understood. Furthermore, whether risks are similar across high burden HIV settings has not been extensively explored. Methods: We harmonized data from two prospective observational studies conducted in Cape Town, South Africa, and Lusaka, Zambia, to compare weight-for-age (WAZ), length-for-age (LAZ) and weight-for-length (WLZ) Z-scores between infants who were HEU and HU, converting infant anthropometric measures using World Health Organisation Growth Standards adjusted for age and sex. Linear mixed effects models were fit to identify risk factors for differences in anthropometrics at 6–10 weeks and 6 months by infant HIV exposures status and by timing of exposure to maternal ART, either from conception or later in gestation. Results: Overall 773 mother-infant pairs were included across two countries: women living with HIV (WLHIV), 51% (n = 395) with 65% on ART at conception and 35% initiating treatment in pregnancy. In linear mixed effects models, WAZ and WLZ at 6–10 weeks were lower among infants who were HEU vs HU [β = − 0.29 (95% CI: − 0.46, − 0.12) and [β = − 0.42 (95% CI: − 0.68, − 0.16)] respectively after adjusting for maternal characteristics and infant feeding with a random intercept for country. At 6 months, LAZ was lower [β = − 0.28 CI: − 0.50, − 0.06)] among infants who were HEU, adjusting for the same variables, with no differences in WAZ and WLZ. Within cohort evaluations identified different results with higher LAZ among infants who were HEU from Zambia at 6–10 weeks, [β = + 0.34 CI: + 0.01, + 0.68)] and lower LAZ among infants who were HEU from South Africa [β = − 0.30 CI: − 0.59, − 0.01)] at 6 months, without other anthropometric differences at either site. Conclusion: Infant growth trajectories differed by country, highlighting the importance of studying contextual influences on outcomes of infants who were HEU.


  • Open Access

    Adherence to Daily Oral Pre-Exposure Prophylaxis (PrEP) During Pregnancy and the Postpartum Period in South African Women: A Cohort Study

    by Dvora L. Joseph Davey, Dorothy Nyemba, Jose Castillo-Mancilla, Lubbe Wiesner, Jennifer Norman, Rufaro Mvududu, Nyiko Mashele, Leigh F. Johnson, Linda-Gail Bekker, Pamina Gorbach, et al.

    Background: Daily pre-exposure prophylaxis (PrEP) use at time of HIV exposure is essential for effectiveness but data on PrEP adherence during pregnancy and postpartum are few. Methods: We enrolled pregnant women without HIV at first antenatal care (ANC) visit followed-up through 12-months postpartum. Eligible women >16 years old received HIV prevention counseling and were offered oral PrEP (TDF-FTC). We quantified tenofovir diphosphate (TFV-DP) levels in dried blood spots and compared these with self-reported adherence in women who had reported taking PrEP in the past 30-days. Logistic regression models with generalized estimating equations evaluated correlates of TFV-DP (any vs. none), and >2 estimated doses/week compared with 20 weeks’ gestation at their first ANC visit. Half of samples had quantifiable TFV-DP at any time point (52%), declining from 67% of pregnant women 3-months post-initiation to 31% of postpartum women at 12-months. Overall, 72% had concentrations corresponding to 5 times vs. 2doses/week vs. <2 doses/week (aOR=1·83;95%CI=1·04-3·20). Interpretation: In pregnant and postpartum women adherence to PrEP using objective measures was low overall and did not correspond to self-reported use. There is an urgent need for adherence support interventions as part of PrEP services for pregnant and postpartum women at risk of HIV. Funding: DJD, TC, LFJ and LM received funding from NIMH (R01MH116771) and NICHD (R01HD106821). DJD received funding from Fogarty International Center (K01TW011187). The University of Cape Town Clinical PK Laboratory is supported in part via the Adult Clinical Trial Group (ACTG), by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health under award numbers UM1 AI068634, UM1 AI068636, and UM1 AI106701; as well as the Infant Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT), funding provided by National Institute of Allergy and Infectious Diseases (U01 AI068632), The Eunice Kennedy Shriver National Institute of Child Health and Human Development, and National Institute of Mental Health grant AI068632. Declaration of Interest: None to declare. Ethical Approval: The PrEP-PP study was approved by the Human Research Ethics Committee of the University of Cape Town Faculty of Health Sciences (#297/2018) and by the University of California, Los Angeles Institutional Review Board (IRB#18-001622). All women provided written informed consent in English or their local language (isiXhosa). Participants were reimbursed for their time for study visits and transportation (equivalent of USD$8 in a grocery voucher).


  • Prevalence of curable STIs and bacterial vaginosis during pregnancy in sub-Saharan Africa: a systematic review and meta-analysis

    by Dorothy Chiwoniso Nyemba, Eposi C Haddison, Colin Wang, Leigh Francis Johnson, Landon Myer, Dvora Joseph Davey

    Objective: STIs remain a global public health problem with a high burden among pregnant women. STIs in pregnant women may lead to various adverse pregnancy outcomes. In most sub-Saharan African countries, syndromic management is used for screening and treatment of STIs. We aimed to update and summarise pooled prevalence of curable STIs and bacterial vaginosis (BV) among pregnant women in sub-Saharan Africa.Methods: Electronic databases and reference lists of relevant published and unpublished studies were searched from March 2015 to October 2020. Studies were included if theyestimated prevalence of Chlamydia trachomatis(CT),Trichomonas vaginalis(TV),Neisseria gonorrhoeae(NG),Treponema pallidum(syphilis),Mycoplasma genitalium(MG) and BV among pregnant women in sub-Saharan Africa. Meta-analyses were performed with observed prevalences corrected for diagnostic errors to estimate the pooled prevalence of diagnosed infections by region.Results: A total of 48 studies met the inclusion criteria, providing 85-point prevalence estimates for curable STIs and BV. Pooled prevalence estimates (with 95% CI and number of women tested) were as follows: MG: 13.5% (4.0–27.2, n=1076); CT: 10.8% (6.9–15.5, n=6700); TV: 13.8% (10.0–18.0, n=9264); NG: 3.3% (2.1–4.7, n=6019); syphilis: 2.9% (2.0–4.0, n=95 308) and BV: 36.6% (27.1–46.6, n=5042). By region, BV was the most prevalent and ranged from 28.5% (24.5–32.8, n=1030) in Eastern Africa to 52.4% (33.5–70.9, n=2305) in Southern Africa; NG had the lowest prevalence, ranging from 1.4% (95% CI 0.1 to 3.1, n=367) in Central Africa to 4.4% (95% CI 2.6 to 6.4, n=4042) in Southern Africa.Conclusion: The prevalence of curable STIs and BV in sub-Saharan Africa is substantial in pregnant women but most prevalent in Southern Africa where HIV prevalence is highest. It is crucial to integrate screening of curable STIs into antenatal care programmes that have previously focused on diagnosis and treatment of syphilis and HIV.


  • Open Access

    Lower birth weight-for-age and length-for-age z-scores in infants with in-utero HIV and ART exposure: a prospective study in Cape Town, South Africa

    by Dorothy C. Nyemba, Emma Kalk, Hlengiwe P. Madlala, Thokozile R. Malaba, Amy L. Slogrove, Mary-Ann Davies, Andrew Boulle, Landon Myer, Kathleen M. Powis

    Background: Successful scale-up of antiretroviral therapy (ART) during pregnancy has minimized infant HIV acquisition, and over 1 million infants are born HIV-exposed but uninfected (HEU), with an increasing proportion also exposed in utero to maternal ART. While benefits of ART in pregnancy outweigh risks, some studies have reported associations between in utero ART exposure and impaired fetal growth, highlighting the need to identify the safest ART regimens for use in pregnancy. Methods: We compared birth anthropometrics of infants who were HEU with those HIV-unexposed (HU) in Cape Town, South Africa. Pregnant women had gestational age assessed by ultrasound at enrolment. Women living with HIV were on ART (predominately tenofovir-emtricitabine-efavirenz) either prior to conception or initiated during pregnancy. Birth weights and lengths were converted to weight-for-age (WAZ) and length-for-age (LAZ) z-scores using Intergrowth-21st software. Linear regression was used to compare mean z-scores adjusting for maternal and pregnancy characteristics. Results: Among 888 infants, 49% (n = 431) were HEU and 51% (n = 457) HU. Of 431 HEU infants, 62% (n = 268) were exposed to HIV and antiretrovirals (ARVs) from conception and 38% (n = 163) were exposed to ARVs during gestation but after conception (median fetal ARV exposure of 21 weeks [IQR; 17–26]). In univariable analysis, infants who were HEU had lower mean WAZ compared with HU [β = − 0.15 (95% Confidence Interval (CI): − 0.28, − 0.020)]. After adjustment for maternal age, gravidity, alcohol use, marital and employment status the effect remained [adjusted β − 0.14 (95%CI: − 0.28, − 0.01]. Similar differences were noted for mean LAZ in univariable [β − 0.20 (95%CI: − 0.42, − 0.01] but not multivariable analyses [adjusted β − 0.18 (95%CI: − 0.41, + 0.04] after adjusting for the same variables. Mean WAZ and LAZ did not vary by in utero ARV exposure duration among infants who were HEU. Conclusion: In a cohort with high prevalence of ART exposure in pregnancy, infants who were HEU had lower birth WAZ compared with those HU. Studies designed to identify the mechanisms and clinical significance of these disparities, and to establish the safest ART for use in pregnancy are urgently needed.